CAR T-Cell Therapy has Redefined the Treatment Algorithm for Relapsed and/or Refractory Diffuse Large B-cell Lymphoma

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

Playback speed

10 seconds

CAR T-Cell Therapy has Redefined the Treatment Algorithm for Relapsed and/or Refractory Diffuse Large B-cell Lymphoma

By University of Louisville FEATURING Mohamed A Kharfan-Dabaja

71 views

March 16, 2023

Mohamed A. Kharfan-Dabaja, M.D., MBA, FACP, Professor of Medicine; Vice Chair, Hematology; Director, Blood and ...
read more ↘ Marrow Transplantation and Cellular Therapies; and Medical Director, Cancer Research Office (Florida Campus) at the Mayo Clinic College of Medicine and Science, focused on discussing the current indications for CAR T-cell therapy in patients with diffuse large B-cell lymphoma, identifying the unique toxicities associated with CAR T-cell therapy, and describing the prognosis associated with CAR T-cell therapy failure and available options.
↖ read less

0 Comments